Monoclonal antibody · Immune activation, directed at PVRIG (CD112R) (PVRIG) · developed by Compugen
COM701 is a humanized monoclonal antibody that binds PVRIG, an immune checkpoint receptor on cytotoxic T lymphocytes and natural killer cells. By blocking PVRIG's interaction with its ligand PVRL2, it is intended to relieve inhibition of T-cell and NK cell activation. It is being studied in multiple cancers, including ovarian, breast, lung, endometrial, colorectal and head and neck cancers, and multiple myeloma, alone or with nivolumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06888921 | Phase 1/2 | Ovarian Cancer | Active not recruiting | CGEN |
| NCT04354246 | Phase 1 | Advanced Cancer | Completed | CGEN |
| NCT03667716 | Phase 1 | Advanced Cancer | Completed | CGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian Cancer RecurrentAdvanced CancerBreast CancerColo-rectal CancerColon CancerEndometrial CancerHNSCCLung CancerLung NeoplasmMicrosatellite Stable Colorectal CarcinomaMultiple MyelomaNeoplasm MalignantOvarian CancerOvarian Neoplasm
Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.
See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEN catalysts and pipeline →